Sevelamer and Other Anion-Exchange Resins in the Prevention and Treatment of Hyperphosphataemia in Chronic Renal Failure

Abstract

Sevelamer, or more precisely ‘sevelamer hydrochloride’, is a weakly basic anion-exchange resin in the chloride form that was introduced in 1997 for the treatment of the hyperphosphataemia of patients with end-stage renal failure, usually those on long-term haemodialysis. The rationale for this therapy was that sevelamer would sequester phosphate within the gastrointestinal tract, so preventing its absorption and enhancing its faecal excretion. Over the succeeding years, large numbers of patients have been treated with sevelamer, and it has fulfilled expectations in helping to control the hyperphosphataemia of end-stage renal failure. However, it is only one of many anion-exchange resins that could be used for this purpose, some of which are currently available for clinical use and are much less costly than sevelamer. Theoretical considerations suggest that some of these other resins might be at least as efficient as sevelamer in sequestering phosphate in the gastrointestinal tract. Neither sevelamer, nor any of these other agents, has been submitted to a proper metabolic balance study to measure the amount of phosphate sequestered by the resin in the bowel, and without this information it is impossible to judge which is the ideal resin for this purpose.

Journal

Journal ID (publisher-id): NEP

Journal ID (nlm-ta): Nephron Physiol

Journal ID (doi): 10.1159/issn.1660-2137

Title: Nephron Physiology

Publisher: S. Karger AG

ISSN (Electronic): 1660-2137

Publication date Subscription-year: 2007

Publication date (Print): September 2007

Publication date (Electronic): 03 August 2007

Volume: 107

Issue: 1

Pages: p17-p33

Affiliations

^aCentre for Nephrology and Department of Physiology, Royal Free and University College Medical School, London, and ^bHarlandwater Services (author formerly of the Permutit Company Ltd.), Leeds, UK

Article

Publisher ID: 106568 Other ID: Nephron Physiol 2007;107:p17–p33

DOI: 10.1159/000106568

PubMed ID: 17675888

Copyright statement: © 2007 S. Karger AG, Basel

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Page count

Figures: 7, Tables: 2, References: 85, Pages: 1

Product

Self URI (application/pdf): https://www.karger.com/Article/Pdf/106568

Self URI (text/html): https://www.karger.com/Article/FullText/106568

Self URI (journal page): https://www.karger.com/SubjectArea/Nephrology

Categories

Subject: Minireview